Transfer Factor as an Option for Managing the COVID-19 Pandemic

Folia Biol (Praha). 2020;66(3):86-90.

Abstract

Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mortality. As no treatment or vaccine may become available before many months, and because occurrence of similar pandemics is only a matter of time, arguments are presented here for testing the effect of transfer factor (TF), an immunomodulator devoid of toxicity, which has been extensively studied in the past for the treatment and prevention of viral infections.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / therapy*
  • Humans
  • Pandemics
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / therapy*
  • Research Design
  • SARS-CoV-2
  • Transfer Factor / therapeutic use*

Substances

  • Adjuvants, Immunologic
  • Transfer Factor